Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010088502 - INSULIN-LIKE GROWTH FACTOR SIGNALING AND INTEGRIN

Publication Number WO/2010/088502
Publication Date 05.08.2010
International Application No. PCT/US2010/022561
International Filing Date 29.01.2010
IPC
A61K 38/24 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
24Follicle-stimulating hormone ; Chorionic gonadotropins, e.g. HCG; Luteinising hormone ; Thyroid-stimulating hormone
C12N 5/02 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
02Propagation of single cells or cells in suspension; Maintenance thereof; Culture media therefor
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides ; , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
C07K 14/65
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
C07K 16/2842
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2839against the integrin superfamily
2842against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US] (AllExceptUS)
  • TAKADA, Yoshikazu [JP]/[US] (UsOnly)
  • SAEGUSA, Jun [JP]/[JP] (UsOnly)
Inventors
  • TAKADA, Yoshikazu
  • SAEGUSA, Jun
Agents
  • CHEN, ShengFeng
Priority Data
61/148,83730.01.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INSULIN-LIKE GROWTH FACTOR SIGNALING AND INTEGRIN
(FR) SIGNALISATION DU FACTEUR DE CROISSANCE ANALOGUE À L'INSULINE ET INTÉGRINE
Abstract
(EN)
Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin binding is disclosed A method for identifying inhibitors of IGFI-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting integrin signaling.
(FR)
La présente invention concerne la découverte selon laquelle l'interaction spécifique entre le facteur de croissance analogue à l'insuline-1 (IGFl) et l'intégrine est impliquée dans la signalisation cellulaire médiée par l'intégrine, comme l'augmentation de la prolifération de cellules exprimant l'intégrine, particulièrement les intégrines αvβ3, α6β1 et α6β4. L'invention concerne ainsi un nouveau procédé permettant d'inhiber la signalisation par les intégrines grâce à l'utilisation d'un inhibiteur de la liaison IGFl-intégrine. L'invention concerne également un procédé permettant d'identifier des inhibiteurs de la liaison IGFl-intégrine. L'invention concerne en outre des polypeptides, des acides nucléiques, et les compositions correspondantes permettant d'inhiber la signalisation par les intégrines.
Also published as
Latest bibliographic data on file with the International Bureau